Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TNF-alpha in asthma.

Mike Berry1, Christopher Brightling, Ian Pavord

  • 1University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.

Current Opinion in Pharmacology
|May 4, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How artificial intelligence could improve the diagnosis and management of COPD: a perspective from GOLD.

American journal of respiratory and critical care medicine·2026
Same author

Preschool wheeze endotypes and their association with asthma attacks and inhaled corticosteroid response.

ERJ open research·2026
Same author

50 years on: how inhaled corticosteroids have changed the treatment of asthma.

The Lancet. Respiratory medicine·2026
Same author

The 2024 UK asthma guidelines: considerations for patients with asthma not responding to maintenance and reliever therapy.

The British journal of general practice : the journal of the Royal College of General Practitioners·2026
Same author

Association of blood eosinophils and exhaled nitric oxide with exacerbations in patients with asthma, COPD and asthma+COPD: the NOVELTY study.

Thorax·2026
Same author

Consortium-Based Patient and Public Involvement and Engagement for Long COVID Research: A Pirit-Focused Impact Evaluation of the PHOSP-COVID Study.

Health expectations : an international journal of public participation in health care and health policy·2026

Refractory asthma, a severe form unresponsive to standard treatments, significantly impacts patient health and healthcare resources. Targeting tumor necrosis factor-alpha (TNF-alpha) with biological agents shows promise for improving lung function and quality of life in these patients.

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Refractory asthma affects 5-10% of asthma patients, leading to significant morbidity, mortality, and high healthcare costs.
  • Limited treatment options exist for refractory asthma, highlighting a substantial unmet clinical need.
  • Tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine, is implicated in airway pathology and potentially crucial in refractory asthma.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting TNF-alpha in patients with refractory asthma.
  • To evaluate the efficacy of anti-TNF-alpha biological agents in managing severe asthma.

Main Methods:

  • Utilized neutralising biological agents targeting TNF-alpha to assess its role in vivo.
  • Preliminary studies involved treating patients with refractory asthma.

Related Experiment Videos

Main Results:

  • Demonstrated improvements in lung function.
  • Showed a reduction in airway hyperresponsiveness.
  • Reported enhanced asthma quality-of-life and decreased exacerbation frequency.

Conclusions:

  • Anti-TNF-alpha therapy represents a promising new treatment avenue for refractory asthma.
  • Targeting TNF-alpha may alleviate symptoms and reduce the burden of severe, difficult-to-treat asthma.